✦ LIBER ✦

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial

✍ Scribed by Davies, Jane; Sheridan, Helen; Bell, Nicholas; Cunningham, Steve; Davis, Stephanie D; Elborn, J Stuart; Milla, Carlos E; Starner, Timothy D; Weiner, Daniel J; Lee, Po-Shun; Ratjen, Felix

Book ID: 122072966
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 423 KB
Volume: 1
Category: Article
ISSN: 2213-2600
DOI: 10.1016/S2213-2600(13)70182-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

53 Lung function, weight, and sweat chlo

53 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis

✍ Plant, B.J.; Konstan, M.; Aherns, R.; Rodriguez, S.; Munck, A.; Elborn, J.S.; Jo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Efficacy and Safety of Ivacaftor in Pati

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

✍ Davies, Jane C.; Wainwright, Claire E.; Canny, Gerard J.; Chilvers, Mark A.; How 📂 Article 📅 2013 🏛 American Thoracic Society 🌐 English ⚖ 646 KB

WS1.1 The effect of ivacaftor, a CFTR po

WS1.1 The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study

✍ De Boeck, K.; Munck, A.; Walker, S.; Faro, A.; Hiatt, P.; Chan, J.; Gilmartin, G 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 70 KB

A CFTR corrector (lumacaftor) and a CFTR

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

✍ Boyle, Michael P; Bell, Scott C; Konstan, Michael W; McColley, Susanna A; Rowe, 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 423 KB

WS7.6 Effect of ivacaftor on lung functi

WS7.6 Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry

✍ J.C. Davies; H. Sheridan; P.-S. Lee; T. Song; A. Stone; F. Ratjen 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

WS23.3 ICM is sensitive to detect potent

WS23.3 ICM is sensitive to detect potentiation of CFTR-mediated Cl− secretion in patients with cystic fibrosis and the G551D mutation treated with ivacaftor

✍ Graeber, S.Y.; Hug, M.J.; Sommerburg, O.; Mainz, J.G.; Heinzmann, A.; Tümmler, B 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB